Dymon Asia Capital (Singapore) Pte. Ltd. Eli Lilly & CO Transaction History
Dymon Asia Capital (Singapore) Pte. Ltd.
- $378 Million
- Q3 2024
A detailed history of Dymon Asia Capital (Singapore) Pte. Ltd. transactions in Eli Lilly & CO stock. As of the latest transaction made, Dymon Asia Capital (Singapore) Pte. Ltd. holds 500 shares of LLY stock, worth $376,705. This represents 0.12% of its overall portfolio holdings.
Number of Shares
500
Previous 300
66.67%
Holding current value
$376,705
Previous $271,000
63.1%
% of portfolio
0.12%
Previous 0.07%
Shares
2 transactions
Others Institutions Holding LLY
# of Institutions
4,003Shares Held
752MCall Options Held
8.27MPut Options Held
10.5M-
Lilly Endowment Inc Indianapolis, IN96.9MShares$73 Billion0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA73.8MShares$55.6 Billion1.2% of portfolio
-
Black Rock Inc. New York, NY65.9MShares$49.6 Billion1.37% of portfolio
-
Pnc Financial Services Group, Inc. Pittsburgh, PA51.4MShares$38.7 Billion29.2% of portfolio
-
State Street Corp Boston, MA33.9MShares$25.5 Billion1.24% of portfolio
About ELI LILLY & Co
- Ticker LLY
- Exchange NYSE
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 950,174,976
- Market Cap $716B
- Description
- Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...